Dr. Ke Chen, our Vice President and Head of API Late phase Process R&D, weighs in on challenges impacting supply management of orphan drugs in an industry roundtable hosted by DCAT Value Chain Insights. Low-volume drug is one of the many cases where challenges are ahead. Nonetheless, our scientists rise to the challenges, fulfilling our mission – every drug can be made and every disease can be treated.
Menu
CONNECT WITH US
